Rus En Es
Main / Portfolio / Endocrinology / Insulin Degludec
  • Basal analogues of human insulin of super long-term effect
  • It is a recombinant human insulin where residual fatty acid is linked to lysine through a linker
  • Provides for an even stable sugar reducing effect lasting for over 42 hours and low intraindividual variability
  • Produced in two concentrations: U100, U200
  • The effect starts in 30–90 min after subcutaneous injection
  • The effect lasts for 42 hours

Development of analogues portfolio Insulin Degludec

GEROPHARM is developing a full line of insulin bio analogues that are at different stages of studying.

Advantages of bio analogues:

  • less variable, more stable effect;
  • economic efficiency.
Name of
the drug
Pharmaceut. Development
Preclinical Trials
Clinical Trials
Insulin Degludec

You are a health care professional?

Go up